Systemic therapy for renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer chemotherapy and biological response modifiers

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0921-4410(04)22012-9PMID 16110616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy

  2005cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

  2003cited by this paper
• Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

  2003cited by this paper
• Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.

  2003cited by this paper
• Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

  2003cited by this paper
• Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

  2003cited by this paper
• Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

  2003cited by this paper
• Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

  2003cited by this paper
• Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.

  2002cited by this paper
• Inhibitors of the vascular endothelial growth factor receptor.

  2002cited by this paper
• Phase II trial of thalidomide for patients with advanced renal cell carcinoma.

  2002cited by this paper
• Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma

  2002cited by this paper
• Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.

  2002cited by this paper
• The treatment of advanced renal cell cancer with high-dose oral thalidomide

  2001cited by this paper
• Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.

  2001cited by this paper
• PTEN/MMAC1/TEP1 mutations in human primary renal‐cell carcinomas and renal carcinoma cell lines

  2001cited by this paper
• Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.

  2000cited by this paper
• Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

  2000cited by this paper
• Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.

  2000cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

  1999cited by this paper
• Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.

  1999cited by this paper
• Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

  1998cited by this paper
• Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

  1997cited by this paper
• Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

  1997cited by this paper
• Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

  1997cited by this paper
• Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

  1997cited by this paper
• Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.

  1995cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

  1994cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.

  1993cited by this paper
• Antitumor and antimetastatic activity of interleukin 12 against murine tumors

  1993cited by this paper
• Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

  1992cited by this paper
• Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.

  1992cited by this paper
• Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.

  1991cited by this paper
• Interleukin-2 toxicity.

  1991cited by this paper
• A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

  1990cited by this paper

• Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication

  2025cites this paper
• Microtubule dynamics is a therapeutic vulnerability in VHL-deficient renal cell carcinoma

  2025influential citation
• RCC-Supporter: supporting renal cell carcinoma treatment decision-making using machine learning

  2024cites this paper
• Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment

  2023cites this paper
• Expression of AKT1 Related with Clinicopathological Parameters in Clear Cell Renal Cell Carcinoma

  2022cites this paper
• Shine, Shine, Ruthenium Caged Drug †

  2022cites this paper
• Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma

  2022cites this paper
• Comparison of cytoreductive partial versus radical nephrectomy in metastatic renal cell carcinoma: To be on the horns of a dilemma

  2022cites this paper
• Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review

  2022cites this paper
• A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Anti-apoptotic Protein in Kidney Cancer

  2022cites this paper
• Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

  2021cites this paper
• MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Quantifying T- and B-cell immune receptor distribution diversity to uncover their clinical relevance in clear cell renal cell carcinoma

  2021cites this paper
• Functional, oncological outcomes and safety of nephron-sparing surgery versus radical nephrectomy in patients with localised renal cell carcinoma with high anatomical complexity: a retrospective cohort study with propensity score matching method

  2021cites this paper
• Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in Renal Cell Carcinoma cell lines.

  2021cites this paper
• Downregulation of the lncRNA ASB16-AS1 Decreases LARP1 Expression and Promotes Clear Cell Renal Cell Carcinoma Progression via miR-185-5p/miR-214-3p

  2021cites this paper
• CMAR_A_330881 7663..7675

  2021cites this paper
• Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?

  2021cites this paper
• CD8+ T Cell-Based Molecular Classification With Heterogeneous Immunogenomic Landscapes and Clinical Significance of Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Prooxidant Activity of Poria Mushroom Extract on Renal Cell Carcinoma: Potential Therapeutic Strategy

  2020cites this paper
• Patterns of Expression of H2S-Producing Enzyme in Human Renal Cell Carcinoma Specimens: Potential Avenue for Future Therapeutics

  2020cites this paper
• Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.

  2020cites this paper
• Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma.

  2019cites this paper
• Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

  2019cites this paper
• LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression

  2019cites this paper
• Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives

  2019cites this paper
• PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma.

  2018cites this paper
• Sequential Use of Targeted Therapies (TT) in Metastatic Renal Cell Cancer (mRCC): Overall Results of a Large Experience

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1512 Neuropilin-1 regulation of tumor vascularization and growth

  2018cites this paper
• Case report : advanced renal cell cancer . When all hope is lost , low dose radiation may help

  2018cites this paper
• Evaluación de los conocimientos generales de los profesionales de la salud ecuatorianos acerca del cáncer renal

  2018cites this paper
• INVESTIGATING THE IMPACT OF INTRAGENIC DNA METHYLATION ON GENE EXPRESSION, AND THE CLINICAL IMPLICATIONS ON TUMOR CELLS AND ASSOCIATED STROMA

  2018cites this paper
• Targeting DNA Methyltranferases in Urological Tumors

  2018cites this paper
• Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

  2017cites this paper
• MicroRNA-138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9.

  2017cites this paper
• Knockdown of Serine–Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells

  2017cites this paper
• Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database.

  2017cites this paper
• In vivo growth and responses to treatment of renal cell carcinoma in different environments.

  2017cites this paper
• Dicholoroacetate exerts anti-cancer activity on human renal cell carcinoma cells

  2017cites this paper
• Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3β/β-catenin signaling pathway

  2017cites this paper
• Large‐scale genome‐wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late‐stage disease

  2017cites this paper
• MicroRNA-497 suppresses renal cell carcinoma by targeting VEGFR-2 in ACHN cells

  2017cites this paper
• Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study.

  2017cites this paper
• In vitro selection of DNA aptamers against renal cell carcinoma using living cell-SELEX.

  2017cites this paper
• Sodium butyrate enhances the growth inhibitory effect of sunitinib in human renal cell carcinoma cells.

  2017cites this paper
• is with in

  2017cites this paper
• Upregulation of FBXW7 Suppresses Renal Cancer Metastasis and Epithelial Mesenchymal Transition

  2017cites this paper
• COMPLICATION AND OUTCOMES ASSOCIATED WITH SURGICAL MANAGEMENT OF RENAL CELL CARCINOMA: LITERATURE REVIEW.

  2017cites this paper
• Management of Atypical Renal Cell Carcinomas

  2017cites this paper
• Synergistic effects of 15-deoxy Δ12,14-prostaglandin J2 on the anti-tumor activity of doxorubicin in renal cell carcinoma

  2016cites this paper
• Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy

  2016cites this paper
• Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

  2016cites this paper
• Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells

  2016cites this paper
• Rho-Associated Kinase 1 (ROCK1) inhibition is Synthetically Lethal with Von Hippel Lindau (VHL) Deficiency in Clear Cell Renal Cell Carcinoma (CC-RCC)

  2016cites this paper
• Antitumour and antiangiogenic activities of [Pt(O,O′‐acac)(γ‐acac)(DMS)] in a xenograft model of human renal cell carcinoma

  2016cites this paper
• Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma

  2016cites this paper
• Active RAS/MEK pathway downregulates expression of IFN-inducible genes by targeting IRF1: implications for understanding molecular mechanisms of viral oncolysis

  2016cites this paper
• High expression of long non-coding RNA lncRNA-ATB is correlated with metastases and promotes cell migration and invasion in renal cell carcinoma.

  2016cites this paper
• Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

  2016cites this paper
• Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma

  2016cites this paper
• Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

  2016cites this paper
• Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study

  2016cites this paper
• High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition

  2016cites this paper
• Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

  2016cites this paper
• Intraperitoneal immunotherapy: historical perspectives and modern therapy

  2016cites this paper
• Effects of CIK on hypoxia inducible factor-1α and T-cell subsets on colon 26 cancer xenograft mice

  2016cites this paper
• Mitogen-Activated Protein Kinases and Hypoxic/Ischemic Nephropathy

  2016cites this paper
• Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma.

  2015cites this paper
• MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer

  2015cites this paper
• Quality of Life of Patients with Advanced/Metastatic Renal Cell Carcinoma During the Treatment Period with Targeted Drugs

  2015cites this paper
• Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study

  2015cites this paper
• Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential.

  2015cites this paper
• Therapeutic challenges in renal cell carcinoma.

  2015cites this paper
• Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.

  2015cites this paper
• Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan

  2015cites this paper
• The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors

  2015cites this paper
• Responses to Overdiagnosis in Thyroid Cancer Screening among Korean Women

  2015cites this paper
• Immunotherapy in Metastatic Renal Cell Carcinoma

  2015cites this paper
• Análisis molecular del carcinoma renal de células claras. Identificación de un perfil de micrornas como factor pronóstico en pacientes en estadio I-II

  2015cites this paper
• Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases

  2014cites this paper
• AB130. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway

  2014cites this paper
• Emphasis of Neutrophil-to-Lymphocyte Ratio in Non-Metastatic Renal Cell Carcinoma

  2014cites this paper
• 1 ASC-J9 ® suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF-2α/VEGF signaling pathway

  2014cites this paper
• Development of renal cell carcinoma (RCC) diagnostics and impact on prognosis

  2014cites this paper
• Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.

  2014cites this paper
• Cytoreductive nephrectomy: past, present and future

  2014cites this paper
• Adäquate Supportivtherapie im therapeutischen Einsatz von „Biologicals“ bei gastrointestinalen(GI) Tumoren in der Onkochirurgie – Was muss der Chirurg wissen?

  2014cites this paper
• Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway

  2014cites this paper
• Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database

  2014cites this paper
• A Case of Metastatic Renal Cell Carcinoma Bleeding of the Pancreas Manifesting As Cholangitis

  2014cites this paper
• RASSF6 promotes p21Cip1/Waf1-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma

  2014cites this paper
• Cadherin-11 in Renal Cell Carcinoma Bone Metastasis

  2014cites this paper
• L’INTÉRÊT DE LA RADIOTHÉRAPIE «ABLATIVE» EN PRENANT COMME MODÈLE LA MÉTASTASE D’UN CANCER RÉNAL À CELLULES CLAIRES

  2014cites this paper
• Potent Anticancer Effects of Bioactive Mushroom Extracts (Phellinus linteus) on a Variety of Human Cancer Cells

  2014cites this paper
• Current management and future perspectives of metastatic renal cell carcinoma

  2014cites this paper
• Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides

  2014cites this paper
• Induction of the Connexin 32 Gene by Epigallocatechin-3-Gallate Potentiates Vinblastine-Induced Cytotoxicity in Human Renal Carcinoma Cells

  2013cites this paper
• Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients

  2013cites this paper
• A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

  2013cites this paper
• Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

  2013cites this paper